hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 10:36:43 - browse：8158

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： UnitedHealth, in a surprise, takes aim at Steward’s physician group

hotspot

entertainment

WSS

Pancreatic cancer is often deadly, but new discoveries are raising hope

Insurer loopholes limit power of law against surprise medical bills

Biden's order seeks to regulate AI risk without stifling innovation

Medicare Advantage 2025 payments will dip, Biden administration says

Alzheimer's risk factor APOE4 may be a distinct form of the disease

The pink breast cancer awareness ribbon needs a redesign

leisure time

hotspot

Gilead needs Arcellx more than ever

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA has safety concerns on CRISPR

Malaria cases in Florida and Texas: Here’s what you need to know

Gut bacteria may contribute to kidney autoimmunity, study finds

As demand for Covid shots wanes, Moderna seeks its next success

Oral obesity drug from Viking Therapeutics hits key early target

Walensky prepares to leave CDC — and Congress — behind

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Medical leaders decry Supreme Court decision on affirmative action

Mass General Brigham physicians react to latest merger step

hotspot

WHO may add ‘noma' to its list of neglected tropical diseases

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Physician subsidies by hospitals soar in wake of No Surprises Act

Scientists uncover potential path to treating deadly childhood tumor

Emergency medicine has repudiated 'excited delirium.' Now what?

Drug companies' payments and gifts affect physicians' prescribing

Wikipedia

hotspot

entertainment

knowledge